Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
17 September 2019 | Story Valentino Ndaba | Photo Valentino Ndaba
Diversity festival
Staff and students come together in celebration at the International Cultural Diversity Festival.


There are 195 countries in the world and the University of the Free State (UFS) officially has a personal relationship with 24 of them. Be it through exchange inbound or outbound programmes or research collaboration, Kovsies is growing its global footprint.

The 2019 International Cultural Diversity Festival brought a mix of music, dance, and poetry to the Bloemfontein Campus on Friday 13 September 2019. The aim of the festival was to recognise, appreciate and celebrate the diverse cultures represented on all our campuses.

Reeling in and rolling out the best talent pool

As stated in the 2018 Internationalisation Report, “Kovsies currently has about 50 international collaboration agreements, and collaboration with 1 584 institutions,” in terms of research. The plan is to widen researchers’ international networks, with a special focus on the African continent.

Finding strength in diversity

“Diversity within groups at the UFS necessitates that we foster a culture of tolerance and a spirit of mutual acceptance and appreciation at our university,” says Chevon Slambee, Chief Officer at the Office for International Affairs (OIA).

Slambee spoke on behalf of the Vice-Rector: Research and Internationalisation, Prof Corli Witthuhn, and the Director of the OIA, Cornelius Hagenmeier, commending the diversity reflected in our international students and staff community.

She mirrored the views of the Kovsie community at large in calling for an end to division and violence based on “othering”. Referring to the upsurge in violence directed against women and people from other countries that we saw in South Africa last month, Slambee remarked: “We are shocked and speechless in light of these events, which are contrary to the spirit of embracing one another’s humanity, which we believe in and want to promote.”

Content photo International
The International Cultural Diversity was filled with entertainment.

A coming together

The festival theme this year was the Boma which is a traditional space created back in the day where a community would sit around the fire, drumming, singing, dancing and listening to tales told by the elders. The UFS strives to be a similar space – growing the current number of international relationships and immersing the institution in the global village – the African way.

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept